Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Files Heart Failure Drug Ivabradine in Japan
December 28, 2018
- Chugai Obtains Approval of First Dual-Function Gene Panel Test
December 28, 2018
- Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
- Xofluza Most Heavily Promoted Drug for GP in October: Anterio
December 27, 2018
- First Cancer Gene Panel Test Approved in Japan: Sysmex
December 27, 2018
- Japan Vaccine to Transfer Business to Daiichi Sankyo, GSK in April
December 27, 2018
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Sumitomo Dainippon to Merge Authorized Generic Units
December 26, 2018
- Fuji Yakuhin Files Hyperuricemia Candidate Dotinurad
December 26, 2018
- Fujifilm, MIT Launch Research Project on Oligonucleotide DDS
December 26, 2018
- INCJ Makes Further Investment in NapaJen Pharma
December 26, 2018
- RaQualia’s Tegoprazan Sublicensed to Vietnam’s Vimedimex
December 26, 2018
- Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
- Takeda Completes M&A Bridge Re-Financing
December 25, 2018
- Mundipharma Files for Japan Approval of Anesthetic Remimazolam
December 25, 2018
- Kyoto Univ., Sumitomo Dainippon, Sumitomo Chemical Team Up for Research on iPS Cell Production
December 25, 2018
- Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial
December 25, 2018
- Daiichi Sankyo Kicks Off 1st Combo Study for Its 2 AML Meds
December 21, 2018
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…